Just a moment, the page is loading...
The Supported Studies Programme

For the latest updates on GSK’s response to COVID-19, please click here.



Please find below some of the current areas of interest for Vaccines Human Subject Research. We are also interested in non-Human Subject Research studies. These were last updated in December 2021.

[Across Diseases & Technologies
General Vaccine Science, life course immunization]
•   Studies assessing the challenges and proposed solutions to implement life course immunization, for both providers and population, taking into account socio-economic-political barriers and utilizing behavioural economics, to improve acceptance and expand coverage
•   Studies on vaccination coverage for all vaccines recommended in adults in groups of countries
•   Studies on vaccination coverage in high risk groups
•   Studies on health care utilization related to the management of infectious diseases (IDs) and all vaccines preventable diseases (VPDs) in older adults in the hospital and post-discharge care settings
•   Studies on quality of life and dependency or other socio-economic consequences following an episode of infectious diseases (IDs) and all vaccine preventable diseases (VPDs) in older adults.
•   Studies on the impact or potential impact of adult vaccination on health systems strengthening and resilience
•   Studies on the impact or potential impact of adult vaccination on health inequalities
•   Studies measuring the impact of communication and educational interventions (in particular if delivered in a digital format) on vaccine coverage, in particular in adults
•   Studies related to trained immunity and its role in secondary infections
•   Studies on the aging parameters of the immune system (immunosenescence) and how they impact the immune response to vaccines of older adults versus young people

[Vaccination behaviours and public-health challenges]
•   Development and implementation of behavioural aspects of immunization
•   Societal factors impacting vaccine coverage
•   Impact of information overload/misinformation - “infodemic”
•   Health communication in vaccine-preventable disease public health
•   Situations where National Immunization Programs do not meet the needs of underserved and vulnerable population
•   Increasing vaccine confidence through community engagement
•   Perceptions and behaviors impacting well-being, lifestyle and infectious disease prevention
•   Vaccine science in plain language accessible to public
•   How decisions about vaccinations are made
•   Communication between Health Care Professionals and patients

[Chronic Obstructive Pulmonary Disease (COPD)]
•   Bacteria and virus prevalence in COPD exacerbations.
•   Impact of the lung microbiome on COPD exacerbations, including the pathogenic role of NTHi, Mcat as well as lung immunity.
•   Bacteria and virus interaction in COPD exacerbations.
•   Identification of biomarkers to assess the risk of COPD exacerbations caused by bacterial and viral infections.
•    Patient’s perspective on vaccination as a tool to support the clinical management of COPD.

[Diphtheria, Tetanus, Pertussis, Haemophilus influenzae type b (Hib), Poliomyelitis]
•   Vaccine effectiveness or impact data, on pertussis, HiB and hepatitis disease following use of DTPa-combinations, in general and special populations.
•   Pertussis burden of diseases/Health Economic studies in young infants, older children, adolescents, adults, older adults and patients with chronic diseases.
•   Pertussis Maternal Immunisation: effectiveness and impact on childhood vaccination.
•   Prevalence and duration of B. pertussis nasopharyngeal carriage in the population.
•   Hexavalent vaccines in reduced schedules in pre-terms.

•   Economic evaluation and societal impact of hepatitis A outbreaks to healthcare utilisation, individuals and societies
•   Hepatitis A seroprevalence data in specific populations
•   Hepatitis B seroprevalence data in specific populations
•   Epidemiology and hepatitis B burden of disease in adults
•   Studies assessing use of hepatitis A, B or A+B vaccine in adult risk groups and other susceptible populations, including but not limited to vaccination coverage rates, knowledge, attitudes and practices medical surveys
•   Impact of Hepatitis A universal vaccination on burden of disease, including use of different schedules
•   Impact of Hepatitis B universal vaccination on burden of disease

[Herpes Zoster
Immunocompetent Older Adults (50 years of age and older)]
•   Observational studies to assess the incidence and burden of disease of HZ, impact of HZ and its complications on quality of Life measures, interference in daily activities, health care costs etc (only when country-specific gap).
•   Observational studies to assess the awareness of risk and impact of shingles, post-herpetic neuralgia (PHN) and other herpes zoster (HZ) complications in older adults.
•   Studies to understand barriers and attitude to vaccination against herpes zoster
•   Studies providing insights into the mechanism of action (adaptive and innate profiling of the vaccine, local immunity, role of the adjuvant system) as it relates to protection.
•   Observational studies to assess the risk of complications (other than PHN)
•   Studies assessing the relationship between COVID-19 or other acute infectious diseases and herpes zoster (shingles) / vaccination
•   Effectiveness and real-world impact of RZV vaccination

[Herpes Zoster
At-Risk/Immunocompromised Adults (18 years of age and older)]
•   Evaluations of safety and/or immunogenicity and/or efficacy of the recombinant zoster vaccine in patients immunocompromised due to disease or therapy, or subjects with co-morbidities (e.g. diabetes, COPD, …).
•   Observational studies to assess the incidence of HZ, impact of HZ and complications on exacerbation/de-stabilization of chronic conditions, Quality of Life and cost of HZ complications.
•   Observational studies to assess awareness of the risk of shingles, PHN and other HZ complications in populations immunosuppressed due to disease and/or therapy, or with chronic conditions.
•   Studies assessing factors impacting knowledge, attitudes and practice to vaccinate those with chronic conditions, or patients immunocompromised due to disease or therapy.
•   Studies providing insights into the mechanism of action (adaptive and innate profiling of the vaccine, local immunity, role of the adjuvant system) as it relates to protection.
•   Incidence/Burden of Illness/Burden of Disease studies (population and country-specific data gaps only).
Reminder: GSK Vaccines supply availability is one of the key criteria in the assessment of the Supported Studies proposals received.

[Human Papillomavirus]
•   Effectiveness or impact of Human Papillomavirus vaccines against vaccine and non-vaccine types and duration of cross protection.
•   Effectiveness of Human Papillomavirus vaccine on non-cervical cancers and pre-cancerous lesions/infections.
•   Alternative schedules for Human Papillomavirus vaccine.
•   Impact of adjuvant in Human Papillomavirus vaccine on humoral and cellular immune responses.
•   Immunogenicity, efficacy, safety in specific populations (immunocompromised, males etc.).

[Influenza (pandemic & seasonal)]
•   Vaccination coverage overall, for quadrivalent influenza vaccines (QIVs), for brand specific vaccines, in WHO- identified risk groups.
•   Co-administration studies.

[Measles, Mumps, Rubella, Varicella (MMRV)]
•   Impact of MMRV combination vaccines on Varicella and MMR coverage.
•   Impact of varicella prevention programs (complications, hospitalization, costs).
•   Effectiveness of GSK MMR vaccine (Measles/Mumps).
•   Burden and severity of Varicella disease.
•   Evidence to better understand the interplay between Varicella programs and herpes zoster disease (role of endogenous/exogenous boosting).
•   MMR/V vaccination strategies (early protection, age groups).

•   Effect of MenB or MenACWY-CRM vaccination programs
•   Evaluating non-B effect of Bexsero on other Neisseria meningitidis serogroups
•   Long term follow-up / Duration of protection of 4CMenB vaccine
•   Co-administration of 4CMenB and Men ACWY-CRM vaccines with HPV, rota or flu vaccines
•   4CMenB booster dose in individuals primed as infants or young children
•   Effect of 4CMenB vaccination in high-risk populations
•   Define immunological correlates of protection against gonorrhea
•   IMD epidemiology post COVID-19

[Streptococcus pneumoniae]
•   Impact / effectiveness of Haemophilus influenzae protein-D conjugated pneumococcal vaccine (on overall disease (Invasive Pneumococcal Disease, Pneumonia, Otitis).
•   Impact / effectiveness (IPD, Pneumonia, Otitis) of Haemophilus influenzae protein-D conjugated pneumococcal vaccine compared to PCV13 (e.g. following vaccine switch, or across regions/countries).

•   Rotavirus (RV) Disease Burden in countries where RV vaccination has not been introduced yet. Preferably with age stratification among infants especially <6 months of age.
•   Impact of RV vaccination on hospitalization, emergency department and outpatient visit due to RVGE/ nosocomial infection/ strain epidemiology and other benefits of RV vaccination
•   Impact of RV vaccination schedule on:
•   Clinical outcomes: mortality, morbidity among children < 5 years
•   Compliance, completion, coverage
•   Health economic benefits
•   Exploring new and innovative approaches for improving Rotavirus Vaccination coverage.
•   Understanding the mechanism of rotavirus infection, immune response, and heterotypic protection
•   Safety among preterm infants

[RSV in vulnerable groups (adults with health conditions, older adults 60 years of age and older)]
•   Epidemiology of RSV: incidence, transmission, genetic diversity, estimates of under-diagnosis
•   Burden of RSV, not limited to:
1. acute respiratory infections
2. hospitalization
3. complications and exacerbations of underlying conditions
4. re-infection
5. quality of life
6. impact on quality of care
7. healthcare resource utilization
8. mortality
9. under-estimation of burden of disease
10. long-term outcomes
•   Direct & indirect cost of RSV disease and RSV-related complications
•   RSV immunology/biology and correlates of protection in natural infections

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.

© 2001-2022 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.